AGP Executive Report
Last update: 2 hours agoPharma Deal Watch: The Angelini family’s U.S. expansion plans are getting concrete after Angelini Pharma targeted Catalyst Pharmaceuticals in Florida, signaling a bigger push for rare-disease innovation beyond Europe. AI for Clinical Trials: NetraMark says it’s expanding adoption of its NetraAI platform, including a first commercial project via CRO partners, as it builds its clinical-development footprint. Biotech Pipeline Update: NovaBridge reported first-half 2026 results and leadership changes, with givastomig moving toward a potential Phase 3 push and VIS-101 progressing toward Phase 2b. Frontier Tech in Rome: AIBC World 2026 kicks off its countdown in Rome, aiming to draw 30,000 delegates and 1,000 exhibitors around AI, blockchain, fintech and digital innovation. OpenAI Ads Go EU (Italy included): OpenAI will start serving ChatGPT ads in 31 European markets on Aug. 24, including Italy, with buying routed through major ad networks. SMB Tech Reality Check: A new FCC move in the U.S. tightens rules on foreign advanced robots, a reminder for startups that hardware supply chains can get hit fast. Fashion Tech for Retail: Turin startup Ustyle is scaling “complete outfit” personalization for e-commerce from a single catalog, targeting higher conversion and order value. Sustainable Tourism (Italy-linked): Italy-backed “Via delle Cascate” in Bosnia is upgrading trails and tourism access, involving local businesses and communities.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
